CN101829163A - Application of rhizoma nardostachyos in preparing medicine for preventing and treating osteoporosis - Google Patents
Application of rhizoma nardostachyos in preparing medicine for preventing and treating osteoporosis Download PDFInfo
- Publication number
- CN101829163A CN101829163A CN200910037875A CN200910037875A CN101829163A CN 101829163 A CN101829163 A CN 101829163A CN 200910037875 A CN200910037875 A CN 200910037875A CN 200910037875 A CN200910037875 A CN 200910037875A CN 101829163 A CN101829163 A CN 101829163A
- Authority
- CN
- China
- Prior art keywords
- rhizoma nardostachyos
- group
- osteoporosis
- preventing
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses new application of rhizoma nardostachyos in preparing a medicine for preventing and treating osteoporosis. Rhizoma nardostachyos has no toxic or side effects and can be prepared into any forms of orally taken medicines singly or together with other medicines having prevention and treatment functions by conventional preparation methods, wherein other medicines having functions of preventing and treating osteoporosis comprise one or more then one of herba epimedii, the root of red-rooted salvia and the root of kudzu vine. The invention is suitable for patients with osteoporosis.
Description
Technical field
The present invention relates to a kind of osteoporotic Chinese medicine that prevents and treat, belong to the field of Chinese medicines.
Technical background
Osteoporosis is the common a kind of bone metabolism disease of old people, and there is trend in advance at the age at present, has become one of international public health problem.Its pathogenesis is also very not clear and definite always, be commonly considered as because of the variation of factors such as hormone regulating and controlling (estrogen, parathyroid hormone, calcitonin and activated vitamin D), nutritional status (calcium, phosphorus, protein and fat etc.), physical factor (motion, daylight), immunologic function and heredity closely related.Show the human endocrine Developmental and Metabolic Disorder, the bone amount of skeleton reduces, the bone fine structure destroys, and bone biomechanical property descends, with the disease of bones quality and quantity.Osteoporotic site of pathological change is human body axial bone and long bone of limbs backbone, and maximum harm is fracture, and common sympton is a pain, sees with lumbago and backache more, accounts for 70%-80%.A very long preclinical phase before taking place, osteoporotic fracture is arranged, the most outstanding during this time performance is exactly an osteodynia, comprise back and extremities joint ache, weak etc., pain spreads to both sides along spinal column, pain relief when dorsal position or seat is stretched after upright or the pain increased when standing for a long time, sitting, in the daytime pain relief, night and early morning increase the weight of when waking up, and bend over, muscular movement, cough, increase the weight of when stool exerts oneself.Present osteoporotic treatment is mainly based on calcium preparation, vitamin D3 class, estrogen, diphosphate etc.
The present invention is to be raw material with this Chinese crude drug, at osteoporotic pathogenesis and clinical symptoms, plays the effect of bone density improving, prevention fracture, thereby reaches prevention and treat osteoporotic purpose.
Chinese invention patent publication number CN1568965A discloses " a kind of medicine for the treatment of osteoporosis and preparation method thereof ", mainly make by Semen sojae atricolor total flavones, Herba Epimedii total flavones, this medicine reaches therapeutic effect by effect of estrogen sample and invigorating the kidney and strengthening the bones effect, but mineral effect in the not mentioned control agent.
Chinese invention patent publication number CN1618451A discloses " a kind of Chinese medicine composition for the treatment of osteoporosis and preparation method thereof ", and its effective ingredient mainly is to be that raw material is made by Cornu Cervi Pantotrichum, Herba Epimedii, Fructus Psoraleae, Herba Cistanches, Fructus Cnidii, Fructus Ligustri Lucidi.Have the kidney invigorating warming YANG, the effect of replenishing essence bone strengthening is applicable to that mainly Chinese medical discrimination belongs to the primary osteoporosis of insufficiency of kidney-YANG pattern of syndrome.Can significantly increase the animal blood calcium, the rising estrogen level, thus realize the osteoporotic purpose of control.
Summary of the invention
The object of the invention provides Radix Et Rhizoma Nardostachyos or the application of its extract in preparation prevention and treatment osteoporosis medicine.
Adopt Radix Et Rhizoma Nardostachyos or its extract as raw material, single with or with other drug regimens with prevention and the effect of treatment osteoporosis routinely formulation method can be prepared into the medicine that is fit to oral any dosage form.Wherein other medicines with prevention and the effect of treatment osteoporosis comprise one or more in Herba Epimedii, Radix Salviae Miltiorrhizae, the Radix Puerariae etc.
The present invention is directed to osteoporotic pathogenesis and clinical symptoms, play the effect of bone density improving, prevention fracture, thereby reach prevention and treat osteoporotic purpose.
The invention will be further elaborated below in conjunction with experimental example
Experimental example 1
1 experimental technique
The SD male rat at 50 3 monthly ages is divided into 5 groups at random, and promptly matched group, model group, administration high dose group and middle dosage group, low dosage are three groups.Every group 10.All the other four groups of rat skin lower injection first are sprinkled Buddhist nun 3.5mg/kg, subcutaneous injection, every day 1 time, continuous 60 days except that matched group.The administration group is irritated stomach simultaneously and is given medicine of the present invention, and Radix Et Rhizoma Nardostachyos decocting liquid adopts conventional decocting method preparation, and the simmer down to respective concentration, and decocting liquid various dose group comprises low dose group (10g/kg), middle dosage group (20g/kg), high dose group (40g/kg); Gastric infusion is respectively organized in medication, and all the other each groups gavage the normal saline of equivalent, experiment successive administration totally 60 days.Measure bone density (BMD) after 60 days, serum osteocalcin (BGP) and serum calcium, phosphorus level.
2 experimental results
Model group and matched group compare, and bone density all significantly reduces (P＜0.01), and medication group and model group are relatively, and bone density all significantly increases (P＜0.05).Model group BGP obviously reduces (P＜0.01) than matched group BGP.Administration group and model group comparison BGP obviously increase (P＜0.05).Administration group and model group compare, and serum calcium, phosphorus content all raise to some extent, and difference has significance meaning (P＜0.05).Illustrate the present invention can control agent in content of mineral substances, bone density improving has certain prevention and therapeutical effect to osteoporosis.
Show every desired value relatively
# and matched group compare, P＜0.01; * compare P＜0.05 with model group; * and model group compare, P＜0.01
Experimental example 2
1 experimental technique
The SD male rat at 50 3 monthly ages is divided into 5 groups at random, and promptly matched group, model group, administration high dose group and middle dosage group, low dosage are three groups.Every group 10.All the other four groups of rat skin lower injection first are sprinkled Buddhist nun 3.5mg/kg, subcutaneous injection, every day 1 time, continuous 60 days except that matched group.
What the administration group irritated simultaneously that stomach gives medicine of the present invention and Herba Epimedii, Radix Salviae Miltiorrhizae, Radix Puerariae fries in shallow oil the water extract altogether, decocting liquid adopts conventional decocting method preparation, and simmer down to respective concentration, decocting liquid various dose group comprises low dose group (15g/kg), middle dosage group (30g/kg), high dose group (60g/kg); Gastric infusion is respectively organized in medication, and all the other each groups gavage the normal saline of equivalent, experiment successive administration totally 60 days.Measure bone density (BMD) after 60 days, serum osteocalcin (BGP) and serum calcium, phosphorus level.
2 experimental results
Model group and matched group compare, and bone density all significantly reduces (P＜0.01), and medication group and model group are relatively, and bone density all significantly increases (P＜0.05); Administration group and model group compare, and BGP, serum calcium, phosphorus content all raise to some extent, and difference has significance meaning (P＜0.05).Illustrate the present invention can control agent in content of mineral substances, bone density improving has certain prevention and therapeutical effect to osteoporosis.
Show every desired value relatively
# and matched group compare, P＜0.01; * compare P＜0.05 with model group; * and model group compare, P＜0.01
Claims (3)
- Radix Et Rhizoma Nardostachyos or its extract list with or with other preventions and treatment osteoporosis agents in the medicine of preparation protect against osteoporosis effect or the application in the health product.
- 2. purposes according to claim 1 is characterized in that: one or more in Radix Et Rhizoma Nardostachyos or its extract and Herba Epimedii, Radix Salviae Miltiorrhizae, the Radix Puerariae are made the medicine with protect against osteoporosis jointly.
- 3. purposes according to claim 1 is characterized in that: described medicine is an oral formulations.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910037875A CN101829163A (en) | 2009-03-13 | 2009-03-13 | Application of rhizoma nardostachyos in preparing medicine for preventing and treating osteoporosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910037875A CN101829163A (en) | 2009-03-13 | 2009-03-13 | Application of rhizoma nardostachyos in preparing medicine for preventing and treating osteoporosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101829163A true CN101829163A (en) | 2010-09-15 |
Family
ID=42713484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200910037875A Pending CN101829163A (en) | 2009-03-13 | 2009-03-13 | Application of rhizoma nardostachyos in preparing medicine for preventing and treating osteoporosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101829163A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102641472A (en) * | 2012-04-27 | 2012-08-22 | 贾沅潽 | Chinese herbal preparation for curing osteoporosis |
| CN103272119A (en) * | 2013-05-03 | 2013-09-04 | 甘肃中脉生物医药科技有限公司 | Traditional Chinese medicine preparation for treating osteoporosis |
| CN105796612A (en) * | 2016-05-18 | 2016-07-27 | 庄信修 | Applications of Chinese pine wood and extract thereof in medicine for treating osteoporosis |
-
2009
- 2009-03-13 CN CN200910037875A patent/CN101829163A/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102641472A (en) * | 2012-04-27 | 2012-08-22 | 贾沅潽 | Chinese herbal preparation for curing osteoporosis |
| CN102641472B (en) * | 2012-04-27 | 2013-12-04 | 贾沅潽 | Chinese herbal preparation for curing osteoporosis |
| CN103272119A (en) * | 2013-05-03 | 2013-09-04 | 甘肃中脉生物医药科技有限公司 | Traditional Chinese medicine preparation for treating osteoporosis |
| CN105796612A (en) * | 2016-05-18 | 2016-07-27 | 庄信修 | Applications of Chinese pine wood and extract thereof in medicine for treating osteoporosis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103893727B (en) | A kind of relieving pain and activating blood circulation relaxing muscles and tendons plaster and preparation method thereof | |
| CN103386008B (en) | Chinese medicine composition for treating endocrine dyscrasia | |
| CN103349753B (en) | Traditional Chinese medicine composition for treating kidney deficiency | |
| CN105288230A (en) | Traditional Chinese medicine composition for treating paralysis | |
| CN1268370C (en) | Capsules for nourishing kidney and strengthening yang | |
| CN106913711A (en) | Treat pharmaceutical composition of knee osteoarthritis and preparation method thereof | |
| CN101829163A (en) | Application of rhizoma nardostachyos in preparing medicine for preventing and treating osteoporosis | |
| CN101485722B (en) | Medicament composition containing drynaria and salvia root, and use thereof | |
| CN101361893B (en) | Traditional Chinese medicine combination for preventing and treating osteoporosis | |
| CN102512647A (en) | Chinese herbal composition for treating abdominal pain due to deficiency-cold | |
| CN102406904A (en) | Traditional Chinese medicine composition for treating vertigo | |
| CN102698050A (en) | Traditional Chinese medicine for treating insomnia | |
| CN105012612A (en) | Traditional Chinese medicine composition for treating hyperosteogeny | |
| CN110934938A (en) | A pharmaceutical composition for foot and its preparation method | |
| CN105535162A (en) | Traditional Chinese medicine for treating osteoporosis | |
| CN1903244A (en) | Traditional Chinese medicine composition for treating sexual disorders | |
| CN1308024C (en) | Medicine for treating diabetes and its preparing method | |
| CN102370838B (en) | Kidney-invigorating and tendon-reinforcing double-phase capsule | |
| CN106728973A (en) | A kind of Chinese medicinal capsule for treating cervical spondylopathy | |
| CN1994415B (en) | Orally administered Chinese medicine for treating dysmenorrhea | |
| CN101862430B (en) | Chinese medicament for treating femoral head necrosis and preparation method thereof | |
| CN1994452A (en) | Orally administered Chinese medicine for treating functional dysmenorrhea | |
| CN104800448A (en) | Traditional Chinese medicine oral liquid for treating spur in heels and preparation method | |
| CN105288149A (en) | Traditional Chinese medicine composition for treating neurasthenia | |
| CN104383211A (en) | Traditional Chinese medicine clysis fluid for treating chronic renal insufficiency and yang deficiency-induced cold of diabetic nephropathy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20100915 |